0001209191-17-002291.txt : 20170105
0001209191-17-002291.hdr.sgml : 20170105
20170105175738
ACCESSION NUMBER: 0001209191-17-002291
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170103
FILED AS OF DATE: 20170105
DATE AS OF CHANGE: 20170105
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Intellia Therapeutics, Inc.
CENTRAL INDEX KEY: 0001652130
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 364785571
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 130 BROOKLINE STREET
STREET 2: SUITE 201
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 857-285-6200
MAIL ADDRESS:
STREET 1: 130 BROOKLINE STREET
STREET 2: SUITE 201
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bell Graeme
CENTRAL INDEX KEY: 0001643757
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37766
FILM NUMBER: 17512155
MAIL ADDRESS:
STREET 1: 1324 WAVERLY ROAD
CITY: GLADWYNE
STATE: PA
ZIP: 19035
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-01-03
0
0001652130
Intellia Therapeutics, Inc.
NTLA
0001643757
Bell Graeme
C/O INTELLIA THERAPEUTICS, INC.
40 ERIE STREET, SUITE 130
CAMBRIDGE
MA
02139
0
1
0
0
EVP, Chief Financial Officer
Stock Option (right to buy)
13.48
2017-01-03
4
A
0
210000
0.00
A
2027-01-02
Common Stock
210000
210000
D
This option was granted on January 3, 2017 with respect to 210,000 shares of Common Stock, with 25% vesting on December 12, 2017 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter.
/s/ Nicole Heifner, attorney-in-fact
2017-01-05